The healthcare and life sciences sectors are bracing for heightened scrutiny from both the U.S. Department of Justice (DOJ) and state Attorneys General (AGs) in 2026. A confluence of factors – including advanced data analytics, increased interagency cooperation, and evolving legal theories – is reshaping the enforcement landscape, promising more complex and potentially costly investigations for companies operating in these highly regulated spaces. This shift demands a proactive approach to compliance, focusing on robust internal governance and a thorough understanding of emerging enforcement priorities.
According to insights shared by Gabriel H. Scannapieco, a partner at Arnall Golden Gregory LLP specializing in healthcare litigation, and Aaron M. Danzig, the evolving tactics of enforcement agencies are significantly shortening investigative timelines. This acceleration is driven by the ability to rapidly analyze large datasets and coordinate efforts across multiple agencies, leading to parallel civil, criminal, administrative, and state-level litigation stemming from a single operational issue. The stakes are rising, and companies must be prepared for a more aggressive and coordinated regulatory response.
Expanding Enforcement Theories and Focus Areas
One key trend is the broadening of False Claims Act (FCA) theories. Traditionally focused on individual instances of fraudulent billing, enforcement is now increasingly targeting enterprise-level systemic issues. This means investigators are examining a company’s overall governance, internal controls, and relationships with vendors to identify potential vulnerabilities. The focus remains strong on managed care organizations, pharmaceutical companies, and instances of medically unnecessary services, but the scope of inquiry is expanding to encompass the entire ecosystem of healthcare delivery.
Scannapieco and Danzig highlight a particularly sensitive area: Medicare Advantage. Scrutiny of risk adjustment practices – the process of accounting for the health status of beneficiaries to determine appropriate payments – is intensifying. This isn’t limited to simply reviewing coding accuracy; investigators are now delving into the design of incentive programs, the utilize of retrospective addenda (changes made to medical records after the fact), and the practices of chart review vendors and documentation tools. Any system that appears to reward coding intensity, potentially leading to inflated payments, is likely to attract attention.
Telehealth Under the Microscope
The rapid expansion of telehealth, accelerated by recent events, has as well drawn the attention of regulators. While prescribing flexibilities have been extended, platforms offering telehealth services continue to face scrutiny, particularly regarding the prescribing of controlled substances. Enforcement efforts are targeting the clinical legitimacy of telehealth encounters, the accuracy of marketing representations, compliance with varying state regulations, and the level of control exercised by physicians in the decision-making process. Ensuring that telehealth services adhere to the same standards of care as in-person visits is paramount.
Cybersecurity and Data Privacy as Enforcement Multipliers
Perhaps one of the most significant developments is the increasing intersection of cybersecurity and healthcare enforcement. Data breaches and privacy failures are no longer viewed as isolated incidents; they are now being leveraged as “enforcement multipliers.” The DOJ is utilizing cyber-fraud theories under the FCA to pursue cases involving compromised patient data. Violations of the California Consumer Privacy Act (CCPA) and the Health Insurance Portability and Accountability Act (HIPAA) are attracting increased attention, particularly concerning the use of tracking technologies in adtech and analytics. Protecting patient data is not only a legal obligation but also a critical component of overall compliance.
The implications of these trends are far-reaching. Companies must invest in robust cybersecurity measures, implement comprehensive data privacy policies, and ensure that their vendors adhere to the same high standards. A proactive approach to risk management, coupled with a commitment to ethical conduct, is essential for navigating this evolving regulatory landscape.
The Role of Advanced Analytics in Investigations
The shift towards data-driven enforcement is a game-changer. Agencies are leveraging advanced analytics to identify patterns of fraud and abuse that would have been difficult to detect using traditional methods. This includes analyzing claims data, identifying outliers, and mapping relationships between providers, patients, and vendors. The ability to quickly process and analyze vast amounts of data allows investigators to focus their resources on the most promising leads, accelerating the pace of investigations.
Navigating Multi-Agency Coordination
The increasing coordination between the DOJ, state AGs, and other regulatory bodies presents a unique challenge for companies facing investigations. A single issue can trigger multiple inquiries, each with its own set of requirements and timelines. Effective communication and coordination with legal counsel are crucial for managing these parallel proceedings and avoiding conflicting obligations. A unified defense strategy is essential for minimizing risk and achieving the best possible outcome.
Looking Ahead: Proactive Compliance is Key
The enforcement trends outlined above suggest a more aggressive and sophisticated regulatory environment for the healthcare and life sciences industries. Companies that prioritize proactive compliance, invest in robust internal controls, and stay abreast of emerging legal developments will be best positioned to mitigate risk and avoid costly penalties. Ignoring these trends is not an option; the consequences of non-compliance can be severe.
Gabriel Scannapieco’s expertise, as highlighted by Arnall Golden Gregory LLP, underscores the importance of understanding the nuances of healthcare enforcement. His profile details his extensive experience in complex civil and criminal litigation, particularly within the healthcare sector. This expertise is invaluable for companies seeking to navigate the increasingly complex regulatory landscape.
As the DOJ and state AGs continue to refine their enforcement strategies, the healthcare and life sciences industries must adapt and evolve. A commitment to ethical conduct, coupled with a proactive approach to compliance, is the best defense against regulatory scrutiny. The coming years will undoubtedly be marked by increased enforcement activity, and companies that are prepared will be best positioned to thrive.
The next significant development to watch will be any further guidance issued by the DOJ regarding its enforcement priorities in the healthcare sector. Stakeholders should also monitor state AG actions and legislative developments related to data privacy and cybersecurity. Staying informed and engaged is crucial for navigating this dynamic regulatory environment.
What are your thoughts on these emerging enforcement trends? Share your insights and experiences in the comments below. Don’t forget to share this article with your colleagues to help them stay informed about the evolving regulatory landscape in healthcare and life sciences.